• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by BrainsWay Ltd.

    10/15/24 6:05:22 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care
    Get the next $BWAY alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
    X None
    Entity Type
    0001505065
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    Brainsway Ltd.
    Jurisdiction of Incorporation/Organization
    ISRAEL
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    Brainsway Ltd.
    Street Address 1 Street Address 2
    16 HARTUM STREET RAD TOWER, 14TH FLOOR, HAR HAHOTZVIM
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    JERUSALEM ISRAEL 9777516 +972-2-582-4030

    3. Related Persons

    Last Name First Name Middle Name
    Levy Hadar
    Street Address 1 Street Address 2
    16 Hartum Street RAD Tower, 14th Floor, Har HaHotzvim
    City State/Province/Country ZIP/PostalCode
    Jerusalem ISRAEL 9777516
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):

    Chief Executive Officer
    Last Name First Name Middle Name
    Marom Ido
    Street Address 1 Street Address 2
    16 Hartum Street RAD Tower, 14th Floor, Har HaHotzvim
    City State/Province/Country ZIP/PostalCode
    Jerusalem ISRAEL 9777516
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):

    Chief Financial Officer
    Last Name First Name Middle Name
    Boehm Ami
    Street Address 1 Street Address 2
    16 Hartum Street RAD Tower, 14th Floor, Har HaHotzvim
    City State/Province/Country ZIP/PostalCode
    Jerusalem ISRAEL 9777516
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):

    Chairman of the Board of Directors
    Last Name First Name Middle Name
    Zacut David
    Street Address 1 Street Address 2
    16 Hartum Street RAD Tower, 14th Floor, Har HaHotzvim
    City State/Province/Country ZIP/PostalCode
    Jerusalem ISRAEL 9777516
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):

    Vice Chairman of the Board of Directors
    Last Name First Name Middle Name
    Hagai Avner
    Street Address 1 Street Address 2
    16 Hartum Street RAD Tower, 14th Floor, Har HaHotzvim
    City State/Province/Country ZIP/PostalCode
    Jerusalem ISRAEL 9777516
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Sarid Karen
    Street Address 1 Street Address 2
    16 Hartum Street RAD Tower, 14th Floor, Har HaHotzvim
    City State/Province/Country ZIP/PostalCode
    Jerusalem ISRAEL 9777516
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Mitrany Eti
    Street Address 1 Street Address 2
    16 Hartum Street RAD Tower, 14th Floor, Har HaHotzvim
    City State/Province/Country ZIP/PostalCode
    Jerusalem ISRAEL 9777516
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Zangen Abraham
    Street Address 1 Street Address 2
    16 Hartum Street RAD Tower, 14th Floor, Har HaHotzvim
    City State/Province/Country ZIP/PostalCode
    Jerusalem ISRAEL 9777516
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Ben Shalom Yossi
    Street Address 1 Street Address 2
    16 Hartum Street RAD Tower, 14th Floor, Har HaHotzvim
    City State/Province/Country ZIP/PostalCode
    Jerusalem ISRAEL 9777516
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Lushi Avner
    Street Address 1 Street Address 2
    16 Hartum Street RAD Tower, 14th Floor, Har HaHotzvim
    City State/Province/Country ZIP/PostalCode
    Jerusalem ISRAEL 9777516
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
    X Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2024-09-29    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
    X Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
    X Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number X None
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    Street Address 1 Street Address 2
    City State/Province/Country ZIP/Postal Code
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US

    13. Offering and Sales Amounts

    Total Offering Amount $20,000,009 USD
    or    Indefinite
    Total Amount Sold $20,000,009 USD
    Total Remaining to be Sold $0 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    This Form D is being filed in connection with the issuance of 2,103,745 ADSs, each representing two ordinary shares of the Company, at a purchase price of $9.50686 per ADS and a warrant to purchase 1,500,000 ADSs at an exercise price of $9.50686 per ADS.

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    1

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $0 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    Brainsway Ltd. /s/ Hadar Levy Hadar Levy Chief Executive Officer 2024-10-15

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $BWAY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BWAY

    DatePrice TargetRatingAnalyst
    11/16/2023Outperform → Mkt Perform
    Raymond James
    3/3/2022$15.00Buy
    Loop Capital
    11/29/2021$14.00 → $15.00Buy
    HC Wainwright & Co.
    8/12/2021$17.00 → $14.00Buy
    HC Wainwright & Co.
    7/19/2021$17.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BWAY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BrainsWay to Showcase Deep TMS at the 2025 American Psychiatric Association Annual Meeting in Los Angeles

      BURLINGTON, Mass. and JERUSALEM, May 01, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, is proud to announce its participation at the American Psychiatric Association (APA) Annual Meeting, taking place May 17–21, 2025, in Los Angeles, California. As part of the meeting's educational programming, there will be a full day master course on Sunday, May 18, 2025, entitled: "Clinical Applications for Psychiatric Practice: Ketamine and TMS." The course will provide an in-depth look at the integration of novel treatments into clinical psychiatric practice, highlighting practical approa

      5/1/25 8:00:00 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • BrainsWay to Report First Quarter 2025 Financial Results on May 13, 2025

      BURLINGTON, Mass. and JERUSALEM, April 29, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its first quarter 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, May 13, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time the same day to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Tuesday, May 13, 2025Time:8:30 AM Eastern TimeUnited States:1-877-300

      4/29/25 8:00:00 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

      Achieved record quarterly sales of $11.4 million in Q4 2024, an increase of 27% compared with Q4 2023 Full year 2024 revenue increased nearly 30% YoY to $41 million Exceeded full year 2024 operating income and Adjusted EBITDA margin guidance Company expects continued strong growth in 2025, with revenue of $49 million to $51 million and further improvement in profit and profitability Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, March 11, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported fourth qua

      3/11/25 7:30:00 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care

    $BWAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by BrainsWay Ltd.

      SC 13G/A - Brainsway Ltd. (0001505065) (Subject)

      11/14/24 1:33:58 PM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by BrainsWay Ltd.

      SC 13G/A - Brainsway Ltd. (0001505065) (Subject)

      11/14/24 1:32:48 PM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D filed by BrainsWay Ltd.

      SC 13D - Brainsway Ltd. (0001505065) (Subject)

      11/13/24 6:09:51 PM ET
      $BWAY
      Medical/Dental Instruments
      Health Care

    $BWAY
    SEC Filings

    See more
    • SEC Form 424B3 filed by BrainsWay Ltd.

      424B3 - Brainsway Ltd. (0001505065) (Filer)

      5/1/25 7:00:47 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by BrainsWay Ltd.

      EFFECT - Brainsway Ltd. (0001505065) (Filer)

      5/1/25 12:15:26 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • SEC Form F-3 filed by BrainsWay Ltd.

      F-3 - Brainsway Ltd. (0001505065) (Filer)

      4/22/25 4:05:48 PM ET
      $BWAY
      Medical/Dental Instruments
      Health Care

    $BWAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Brainsway downgraded by Raymond James

      Raymond James downgraded Brainsway from Outperform to Mkt Perform

      11/16/23 7:31:55 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • Loop Capital initiated coverage on BrainsWay with a new price target

      Loop Capital initiated coverage of BrainsWay with a rating of Buy and set a new price target of $15.00

      3/3/22 4:42:28 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • HC Wainwright & Co. reiterated coverage on BrainsWay with a new price target

      HC Wainwright & Co. reiterated coverage of BrainsWay with a rating of Buy and set a new price target of $15.00 from $14.00 previously

      11/29/21 6:24:14 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care

    $BWAY
    Financials

    Live finance-specific insights

    See more
    • BrainsWay to Report First Quarter 2025 Financial Results on May 13, 2025

      BURLINGTON, Mass. and JERUSALEM, April 29, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its first quarter 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, May 13, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time the same day to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Tuesday, May 13, 2025Time:8:30 AM Eastern TimeUnited States:1-877-300

      4/29/25 8:00:00 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

      Achieved record quarterly sales of $11.4 million in Q4 2024, an increase of 27% compared with Q4 2023 Full year 2024 revenue increased nearly 30% YoY to $41 million Exceeded full year 2024 operating income and Adjusted EBITDA margin guidance Company expects continued strong growth in 2025, with revenue of $49 million to $51 million and further improvement in profit and profitability Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, March 11, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported fourth qua

      3/11/25 7:30:00 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • BrainsWay to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025

      BURLINGTON, Mass. and JERUSALEM, Israel, Feb. 24, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its fourth quarter and full year 2024 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, March 11, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Tuesday, March 11, 2025Time:8:30 AM Eastern TimeUnited

      2/24/25 8:00:00 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care

    $BWAY
    Leadership Updates

    Live Leadership Updates

    See more
    • BrainsWay Appoints Richard A. Bermudes, M.D. as Chief Medical Officer

      BURLINGTON, Mass. and JERUSALEM, Aug. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Richard A. Bermudes, M.D. as Chief Medical Officer (CMO), effective September 1, 2024. Dr. Aron Tendler, M.D., who has served as CMO since 2015, will continue to serve as a collaborator on important strategic research projects. "We are excited to have Richard join our team to lead and shape BrainsWay's clinical strategy and product roadmap. His extensive experience with TMS and brain stimulation therapies as a practicing phys

      8/29/24 7:30:00 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • Murchinson Takes Action to Replace Board of Directors of Nano Dimension at Upcoming Annual General Meeting

      Highlights Entrenchment Tactics Taken by the Board Before and Following March Special Meeting Where Shareholders Overwhelmingly Supported Murchinson's Case for Change – Including the Removal of CEO and Chairman Yoav Stern From the Board Puts Forward Proposals to Improve Company's Failed Corporate Governance by Seeking to Remove All Current Directors and Appoint Five New, Experienced and Independent Nominees Murchinson Ltd. (collectively with its affiliates and funds it advises and/or sub-advises, "Murchinson" or "we"), a significant shareholder with approximately 5.9% of the outstanding shares of Nano Dimension Ltd., a company incorporated in Israel (NASDAQ:NNDM) ("Nano Dimension" or th

      8/3/23 3:00:00 PM ET
      $BWAY
      $INSG
      $MCK
      $NNDM
      Medical/Dental Instruments
      Health Care
      Telecommunications Equipment
      Telecommunications
    • BrainsWay Announces Appointment of Ido Marom as CFO

      BURLINGTON, Mass. and JERUSALEM, May 23, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Ido Marom, an experienced senior financial leader in global industries, including medical technology, as Chief Financial Officer (CFO). Mr. Marom will succeed Scott Areglado, who will be stepping down from the Company to pursue other opportunities. "We are thrilled to welcome Ido and his extensive financial expertise to BrainsWay," stated Hadar Levy, BrainsWay's Chief Executive Officer. "He has led the financial strategy and i

      5/23/23 7:30:00 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care